IL6 and neoplasm: Finally, we compared the OS of this group (13 patients) to the group of patients bearing a tumor with high stromal IL-6 and low cancer cell LC3 (n = 7) and the group of patients bearing a tumor with other combinations (n = 10), and again the former group showed a better survival rate (Figure 4C; p = 0.018).